Insulin and polycystic ovary syndrome: A new look at an old subject

Gynecological Endocrinology

Volumn 12, Issue 4, 1998, Pages 277-292

  Ciampelli, M ^a   Lanzone, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Insulin; Polycystic ovary syndrome; Therapy

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; INSULIN RECEPTOR; METFORMIN; NALTREXONE; SOMATOSTATIN DERIVATIVE; TROGLITAZONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOMETRIUM CANCER; FEMALE; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; OBESITY; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PATHOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING;

EID: 0031712496     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599809015601     Document Type: Review

References (127)

1. Stein IF, Leventhal ML. Amenorrhea associated with bylateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-9
2. Ehrman DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrinol Rev 1995;16: 322-53
3. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61
4. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989;31:87-120
5. Lanzone A, Fulghesu AM, Andreani CL, et al. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Hum Reprod 1990;5:143-9
6. Poretsky L, Kalin MF. The gonadotrophic function of insulin. Endocrinol Rev 1987;8:132-41
7. Gibson M. Reproductive health and polycystic ovary syndrome. Am J Med 1995;98:67S-75S
8. Rutanen EM, Stenman S, Blum W, et al. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab 1993;77:199-204
9. Nagaman N, Hannigan EV, van Dinh T, et al. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988;67: 144-8
10. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-I: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990;11:443-53
11. Julkunen M, Koistinen R, Aalto-Setala K, et al. Primary structure of human insulin-like growth factor-binding protein/placental protein 12 and tissue specific expression of its mRNA. FEBS Letters 1988;236:295-302
12. Rutanen EM, Pekonen F, Makinene T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab 1988;66:173-80
13. Giudice LC, Dsupin BA, Irwin JC. Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. J Clin Endocrinol Metab 1992;75:1235-41
14. Kazeer RR. Insulin resistance, insulin-like growth factor-I and breast cancer: an hypothesis. Int J Cancer 1995;62:403-6
15. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403-7
16. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996;7:605-25
17. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res 1994;14:2113-7
18. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818-24
19. Toniolo P, Whittemore AS. Re: 'Polycystic ovaries and the risk of breast cancer'. Am J Epidemiol 1992;136:372-3
20. Dahlgren E, Johansson S, Lindstet G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-13
21. Dunaif A, Segal K, Futterweit W, et al. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-74
22. Harris MI, Hadden WC, Knowler WC. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years. Diabetes 1987;36:523-34
23. Lanzone A, Caruso A, Di Simone N, et al. Polycystic ovary syndrome: a risk factor for gestational diabetes? J Reprod Med 1995;40:312-6
24. Lanzone A, Fulghesu AM, Cucinelli F, et al. Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Hum Reprod 1996;11:2107-13
25. Sepe JS, Connel FA, Geiss LS, et al. Incidence, maternal characteristics, and perinatal outcome. Diabetes 1985;34:13-6
26. Pfeifle B, Ditschuneit H. Effect of insulin on the growth of cultured arterial smooth muscle cells. Diabetologia 1981;20:155-8
27. King GL, Goodman D, Buzney S, et al. Receptors and growth promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75: 1028-36
28. Oppenheimer MJ, Sundquist K, Bierman EL. Down regulation of high density lipoprotein receptor in human fibroblast by insulin and IGF-I. Diabetes 1989;38:117-22
29. Weidmann P, De Courten M, Bohlen L. Insulin resistance, hyperinsulinemia and hypertension. J Hypertens 1993;11:S27-S38
30. Wild RA, Painter PD, Coulson PB, et al. Lipoprotein lipid concentrations as cardiovascular risk in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-50
31. von Eckardstein S, von Eckardstein A, Bender HG, et al. Elevated low-density lipoproteincholesterol in women with polycystic ovary syndrome. Gynecol Endocrinol 1996;10:311-8
32. Graf MJ, Richards CJ, Brown V, et al. The independent effect of hyperandrogenemia, hyperinsulinemia and obesity on lipid and lipoproteins profiles in women. Clin Endocrinol 1990; 33:119-31
33. Meirow D, Raz I, Yossepowitch O, et al. Dyslipidemia in polycystic ovarian syndrome: different groups, different aetiologies. Hum Reprod 1996;11:1848-53
34. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996;44:277-84
35. Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol 1992;37:119-25
36. Rebuffe-Scrive M, Cullberg G, Lundberg PA, et al. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989; 21:391-7
37. Mattson LA, Cullberg G, Hamberger L, et al. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril 1984;42:579-84
38. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992;75:508-13
39. Holte J, Gennarelli G, Berne C, et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of prehypertensive state? Hum Reprod 1996;11:23-8
40. Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996;45:623-9
41. Lissner L, Bengtsson C, Lapidus L, et al. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992;20:797-801
42. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease. Atherosclerosis 1992;95:105-17
43. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: a risk factor for recurrent myocardial infarction. Lancet 1987;330:3-9
44. Vague P, Juan Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-3
45. Dahlgren E, Janson PO, Johansson S, et al. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994; 61:455-60
46. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604
47. Wild RA, Grubb B, Hartz A, et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-9
48. Prelevic GM. Insulin resistance in polycystic ovary syndrome. Curr Opin Obstet Gynecol 1997; 9:193-201
49. Goldfine ID. The insulin receptor: molecular biology and transmembrane signaling. Endocrinol Rev 1987;8:235-55
50. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 1988;82:1151-6
51. Seino S, Seino M, Bell GI. Human insulin receptor gene: partial sequence and amplification of exons by polymerase chain reaction. Diabetes 1990;39:123-8
52. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996;66:942-7
53. Waterworth DM, Bennet ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polimorphism with polycystic ovary syndrome. Lancet 1997;349:986-9
54. Talbot JA, Bicknell EJ, Rajkhowa M, et al. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996;81:1979-83
55. Krook A, Kumar S, Laing I, et al. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 1994;43: 357-68
56. Sobrara LR, Tang Z, Cama A, et al. Absence of insulin receptor gene mutations in the insulin receptor gene. Metabolism 1994;43:1568-74
57. Flier JS, Eastmen RC, Minaker KL, et al. Acanthosis nigricans in obese women with hyperandrogenism: characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985;34:101-7
58. Jalal I, Naiker P, Reddi K, et al. Evidence for insulin resistance in non-obese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987;64:1066-9
59. Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity: in vivo and in vitro studies of hyperandrogenic females. Diabetes 1991;40:693-700
60. Pedersen O, Hjollund E, Lindkskov HO. Insulin binding and action on fat cells from young healthy females and males. Am J Physiol 1982;243: E158-67
61. Ciaraldi TP, El-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75:577-83
62. Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-66
63. Marsden PJ, Murdoch A, Taylor R. Severe impairment of insulin action in adipocytes from amenorrhoic subjects with polycystic ovary syndrome. Metabolism 1994;43:1536-42
64. Ciaraldi TP, Morales AJ, Hickman MG. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involve adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997;82:1421-4
65. Conway GS, Avey C, Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinemia and polycystic ovary syndrome. Hum Reprod 1994;9: 1681-3
66. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J Clin Invest 1995; 96:801-10
67. Takajama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988;263:3440-7
68. Karasik A, Rochenberg PL, Yamada K, et al. Increased protein kinase C activity is linked to reduced insulin receptor authophosphorylation in liver of starved rats. J Biol Chem 1990;265: 10226-30
69. Ciaraldi TP. The role of adenosine in insulin action coupling in rat adipocytes. Mol Cell Endocrinol 1988;60:31-41
70. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT4 glucose transporters in adipocytes. Am J Physiol 1993;264: E197-E202
71. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976;294:739-45
72. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in non obese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57: 356-62
73. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogcnism. Fertil Steril 1988;50:197-212
74. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6
75. Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983;147:588-92
76. Dunaif A, Futterweit W, Segal KR, et al. Profound peripheral insulin resistance, independent from obesity, in the polycystic ovary syndrome. Diabetes 1989;38:1165-74
77. O'Meara NM, Blackman JD, Ehrman DA, et al. Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76:1241-7
78. Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-64
79. Ovesen P, Moller J, Ingerslev HJ, et al. Normal basal and insulin stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1993;77:1636-40
80. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Heterogeneity in β-cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997;12:1897-901
81. Holte J, Bergh T, Berne C, et al. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994;78:1052-8
82. Ehrman DA, Sturis J, Byrne MM, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1996:520-7
83. Norman RJ, Mahabeer S, Masters S. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil Steril 1995; 63:58-62
84. Dunaif A, Sorbara L, Delson R, et al. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 1993;42:1462-8
85. Holte J, Bergh T, Berne C, et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight-loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-93
86. Ciampelli M, Fulghesu AM, Murgia F, et al. Acute insulin response to intravenous glucagon in polycystic ovary syndrome. Hum Reprod 1998; 13:847-51
87. Buffington CK, Kitabchi AE. Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. Metabolism 1994;11:1367-72
88. Faber OK, Christensen K, Kehletm H, et al. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 1981;53:618-21
89. Bonora E, Zavaroni I, Bruschi F, et al. Peripheral hyperinsulinemia of simple obesity: pancreatic hypersecretion of impaired insulin metabolism? J Clin Endocrinol Metab 1984;59:1121-7
90. Fulghesu AM, Ciampelli M, Fortini A, et al. Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. Hum Reprod 1995;10: 2253-7
91. Scheen AJ. Perspective in the treatment of insulin resistance. Hum Reprod 1997;12(Suppl. 1):63-71
92. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44: 611-6
93. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68: 173-9
94. Slabber M, Barnard HL, Kuyl JM, et al. Effects of a low insulin response, energy restricted diet on weight loss and plasma insulin concentrations in hyperinsulinemic obese females. Am J Clin Nutr 1994;60:48-53
95. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993;39:1-16
96. Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604
97. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36:105-11
98. Bates GW, Whitworth NS. Effects of body weight reduction on plasma androgens in obese infertile women. Fertil Steril 1982;38:406-9
99. Ipp E, Dobbs R, Unger RH. Morphine and β-endorphins influence the secretion of the endocrine pancreas. Nature 1978;276:190-1
100. Giugliano D, Ceriello A, Salvatore T, et al. β-endorphin infusion restores acute insulin responses to glucose in type-2 diabetes mellitus. J Clin Endocrinol Metab 1987;64:944-8
101. Givens JR, Wiedemann E, Andersen RM, et al. β-endorphin and β-lipothropin plasma levels in hirsute women: correlation with body weight. J Clin Endocrinol Metab 1980;50:975-6
102. Givens JR, Kurtz BR, Kitabchi AE, et al. Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade. J Clin Endocrinol Metab 1987;64:377-82
103. Fulghesu AM, Lanzone A, Cucinelli F, et al. Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 1993; 82:191-7
104. Lanzone A, Fulghesu AM, Fortini A, et al. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic disease. Hum Reprod 1991;6:1043-9
105. Lanzone A, Fulghesu AM, Cucinelli F, et al. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovary syndrome: relationship with insulin and luteinizing hormone secretion. J Clin Endocrinol Metab 1995;80:3501-7
106. Fulghesu AM, Ciampelli M, Guido M, et al. Role of opioid cone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. Metabolism 1998;47:1-5
107. Brazeau JC, Vale W, Burgus N, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-7
108. Kuhn JM, Basin C, Mollard M, et al. Effects of the new somatostatin-analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest 1992;22:793-9
109. Prelevic GM, Wurzburger MI, Balint-Peric L, et al. Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990;336:900-3
110. Prelevic GM, Wurzburger MI, Balint-Peric L, et al. Effects of somatostatin analogue, octreotide, in polycystic ovary syndrome. Metabolism 1992;9: 76-9
111. Fulghesu AM, Lanzone A, Andreani CL, et al. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 1995;64:703-8
112. Hoffman CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabet Care 1992;15:1075-8
113. Nolan JJ, Ludvick B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93
114. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81: 3299-306
115. Ehrman DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-16
116. Riccio A, Del Prato S, Vigili de Kreutzenberg S, et al. Glucose and lipid metabolism in non-insulin dependent diabetes. Effect of metformin. Diabetes Metab 1991;17:180-4
117. Widen E, Eriksson J, Group L. Metformin normalizes non-oxidative glucose metabolism in normoglycemic individuals at increased risk of non-insulin-dependent diabetes. Diabetes 1992; 41:354-8
118. Matthei S, Hamann A, Klein HH, et al. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 1991;40: 850-7
119. Velazquez EM, Mendoza SG, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
120. Velazquez EM, Mendoza SG, Wang P, et al. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a) and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997;46:454-7
121. Velazquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90: 392-5
122. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1997; 335:617-23
123. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex-hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-62
124. Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946-9
125. Ehrman DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-30
126. Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In Mogensen CE, Standl E, eds. Pharmacology of Diabetes. Berlin, New York: Walter de Gruyter, 1991:357-99
127. Geisthovel F, Frorath B, Brabant G. Acarbose reduces elevated testosterone serum concentrations in hyperinsulinemic premenopausal women: a pilot study. Hum Reprod 1996;11: 2377-81